or Try an Advanced Search...

    Technical Analysis for NVCR - NovoCure Limited

    Grade Last Price % Change Price Change
    C 16.65 -1.25% -0.21
    NVCR closed up 2.31 percent on Wednesday, November 20, 2024, on 67 percent of normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline. Its advance stalled at its 200 day moving average, an important long-term support / resistance line.
    2 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Up Down
    Historical NVCR trend table...
    Date Alert Name Type % Chg
    200 DMA Resistance Bearish -1.25%
    Crossed Above 20 DMA Bullish -1.25%
    Crossed Above 50 DMA Bullish -1.25%
    Bollinger Band Squeeze Range Contraction -1.25%
    50 DMA Resistance Bearish 1.03%
    Bullish Engulfing Bullish 1.03%
    Bollinger Band Squeeze Range Contraction 1.03%
    Outside Day Range Expansion 1.03%
    Bollinger Band Squeeze Range Contraction 5.84%
    NR7 Range Contraction 5.84%
    Older End-of-Day Signals for NVCR ...

       Recent Intraday Alerts

    Alert Time
    50 DMA Support about 1 hour ago
    Down 3% about 1 hour ago
    Down 2 % about 1 hour ago
    60 Minute Opening Range Breakdown about 2 hours ago
    Fell Below 50 DMA about 2 hours ago
    View Earlier Intraday Alerts

    Free Daily (Stock) Chart Reading

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    NVCR Chart by TradingView
    Basic chart:

    Profile

    NovoCure Limited develops and commercializes treatment for solid tumor cancers therapy called the tumor treating fields (TTFields). The company markets its proprietary therapy, TTFields delivery system under the Optune name for use as a monotherapy treatment for adult patients with glioblastoma brain cancer. NovoCure Limited also conducts clinical trials for the use of TTFields in brain metastases, advanced non-small cell lung cancer, pancreatic cancer, ovarian cancer, and mesothelioma. The company markets its products in the United States, as well as in European Union member states, Switzerland, and Japan. NovoCure Limited was founded in 2000 and is based in Saint Helier, Channel Islands.
    Classification
    Sector: Healthcare
    Industry: Medical Instruments & Supplies
    Keywords: Medicine Cancer Clinical Medicine Oncology Tumor Non Small Cell Lung Cancer Ovarian Cancer Pancreatic Cancer Small Cell Lung Cancer Blastoma Glioblastoma Brain Tumor Solid Tumor Cancers Aging Associated Diseases Brain Cancer Metastases Mesothelioma

    Is NVCR a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Nov 21 Novocure Data at 2024 SNO Annual Meeting Highlights Product Innovation and Real-World Evidence for Tumor Treating Fields (TTFields) Therapy in Glioblastoma
    Nov 21 FDA Approves Novocure’s Innovative HFE Transducer Arrays for Use With Optune Gio® for Glioblastoma
    Oct 31 NovoCure’s Strong Q3 and Leadership Changes in 2024
    Oct 31 NovoCure Ltd (NVCR) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid Strategic ...
    Oct 31 NovoCure (NVCR) Q3 2024 Earnings Call Transcript
    Oct 30 NovoCure Limited (NVCR) Q3 2024 Earnings Conference Call Transcript
    Oct 30 NovoCure (NVCR) Reports Q3 Loss, Tops Revenue Estimates
    Oct 30 Novocure appoints Moderna's exec Christoph Brackmann as CFO
    Oct 30 NovoCure: Q3 Earnings Snapshot
    Oct 30 Novocure Appoints Christoph Brackmann as Chief Financial Officer
    See more NVCR news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 24.735
    52 Week Low 11.31
    Average Volume 1,008,397
    200-Day Moving Average 17.10
    50-Day Moving Average 16.52
    20-Day Moving Average 16.85
    10-Day Moving Average 17.07
    Average True Range 1.08
    RSI (14) 50.74
    ADX 19.34
    +DI 26.92
    -DI 19.52
    Chandelier Exit (Long, 3 ATRs) 15.42
    Chandelier Exit (Short, 3 ATRs) 18.35
    Upper Bollinger Bands 18.40
    Lower Bollinger Band 15.30
    Percent B (%b) 0.5
    BandWidth 18.43
    MACD Line 0.04
    MACD Signal Line 0.13
    MACD Histogram -0.097
    Fundamentals Value
    Market Cap 1.8 Billion
    Num Shares 107 Million
    EPS -1.86
    Price-to-Earnings (P/E) Ratio -9.06
    Price-to-Sales 3.35
    Price-to-Book 4.16
    PEG Ratio -0.47
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 18.56
    Resistance 3 (R3) 18.53 17.94 18.27
    Resistance 2 (R2) 17.94 17.51 17.95 18.18
    Resistance 1 (R1) 17.40 17.24 17.67 17.43 18.08
    Pivot Point 16.81 16.81 16.95 16.82 16.81
    Support 1 (S1) 16.27 16.38 16.54 16.30 15.64
    Support 2 (S2) 15.68 16.11 15.69 15.54
    Support 3 (S3) 15.14 15.68 15.45
    Support 4 (S4) 15.17